CD274 and colorectal carcinoma: These include evaluation of the PD-L1 inhibitor atezolizumab plus FOLFOX compared to FOLFOX alone in MSI-H CRC patients [62], and evaluation of the anti-PD-L1 compound avelumab following 5-FU-based treatment compared to 5-FU-based treatment alone in patients with stage III MSI-H or POLE-mutant CRC [63].